IL9 and diffuse large B-cell lymphoma: Wang and colleagues reported elevated serum levels of IL-9 in B cells from non-Hodgkin’s lymphoma and diffuse large B-cell lymphoma (DLBCL) patients [75], along with high levels of IL-9R expression in tumoral tissues that correlate with adverse prognostic markers of the disease [76].